Evidence map›Paper›PMID 28149957›Full record

ArticleACS central science2017

Illuminating Phenylazopyridines To Photoswitch Metabotropic Glutamate Receptors: From the Flask to the Animals.

Xavier Gómez-Santacana, Silvia Pittolo, Xavier Rovira, Marc Lopez, Charleine Zussy, James A R Dalton, Adèle Faucherre, Chris Jopling, Jean-Philippe Pin, Francisco Ciruela and 4 more

Abstract read
In one paragraph

Article in ACS central science, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Light-Activated Agonist-Potentiator of GABAJournal of the American Chemical Society · 2024
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. BTDAzo: A Photoswitchable TRPC5 Channel Activator.Angewandte Chemie (International ed. in English) · 2022
    Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Reversible silencing of endogenous receptors in intact brain tissue using 2-photon pharmacology.Proceedings of the National Academy of Sciences of the United States of America · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Xavier Gómez-SantacanaMCS, Laboratory of Medicinal Chemistry & Synthesis, Institute for Advanced Chemistry of Catalonia (IQAC-CSIC), Barcelona, Spain; Institute for Bioengineering of Catalonia (IBEC), Barcelona, Spain; Institut de Neurociències and Unitat de Bioestadística, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
Silvia PittoloInstitute for Bioengineering of Catalonia (IBEC) , Barcelona, Spain.
Xavier RoviraInstitute of Functional Genomics, Université de Montpellier, Unité Mixte de Recherche 5302 CNRS, Montpellier, France; Unité de recherche U1191, INSERM, Montpellier, France.
Marc LopezUnitat de Farmacologia, Departament Patologia i Terapèutica Experimental, Facultat de Medicina, IDIBELL, Universitat de Barcelona, Barcelona, Spain; Institut de Neurociències, Universitat de Barcelona, Barcelona, Spain.
Charleine ZussyInstitute of Functional Genomics, Université de Montpellier, Unité Mixte de Recherche 5302 CNRS, Montpellier, France; Unité de recherche U1191, INSERM, Montpellier, France.
James A R DaltonInstitut de Neurociències and Unitat de Bioestadística, Universitat Autònoma de Barcelona (UAB) , Barcelona, Spain.
Adèle FaucherreInstitute of Functional Genomics, Université de Montpellier, Unité Mixte de Recherche 5302 CNRS, Montpellier, France; Unité de recherche U1191, INSERM, Montpellier, France.
Chris JoplingInstitute of Functional Genomics, Université de Montpellier, Unité Mixte de Recherche 5302 CNRS, Montpellier, France; Unité de recherche U1191, INSERM, Montpellier, France.
Jean-Philippe PinInstitute of Functional Genomics, Université de Montpellier, Unité Mixte de Recherche 5302 CNRS, Montpellier, France; Unité de recherche U1191, INSERM, Montpellier, France.
Francisco CiruelaUnitat de Farmacologia, Departament Patologia i Terapèutica Experimental, Facultat de Medicina, IDIBELL, Universitat de Barcelona, Barcelona, Spain; Institut de Neurociències, Universitat de Barcelona, Barcelona, Spain.
Cyril GoudetInstitute of Functional Genomics, Université de Montpellier, Unité Mixte de Recherche 5302 CNRS, Montpellier, France; Unité de recherche U1191, INSERM, Montpellier, France.
Jesús GiraldoInstitut de Neurociències and Unitat de Bioestadística, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain; Network Biomedical Research Center on Mental Health (CIBERSAM), Madrid, Spain.
Pau GorostizaInstitute for Bioengineering of Catalonia (IBEC), Barcelona, Spain; Network Biomedical Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Madrid, Spain; Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Spain.
Amadeu LlebariaMCS, Laboratory of Medicinal Chemistry & Synthesis, Institute for Advanced Chemistry of Catalonia (IQAC-CSIC) , Barcelona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Phenylazopyridines are photoisomerizable compounds with high potential to control biological functions with light. We have obtained a series of phenylazopyridines with light dependent activity as negative allosteric modulators (NAM) of metabotropic glutamate receptor subtype 5 (mGlu

Identifiers

PMID28149957
PMCPMC5269660

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.